|
|
|
|
|
|
|
|
|
Outsourced Pharma Capabilities Update - ADCs
|
This digital event focuses on antibody-drug conjugates (ADCs) and how CDMOs support their development from early stages through clinical and commercial manufacturing. It highlights the importance of selecting the right partner for these complex therapies, including expertise in conjugation processes, scalability, regulatory needs, and integrated development services. Attendees will learn key criteria for evaluating CDMOs and how to align partnerships to accelerate ADC program success. Click here to learn more.
|
|
|
|
|
|
|
|
|
|
|
|
The Top Tech Transfer Risks At Multi-Site CDMOs
|
|
Article | By Josh Clark, Steve Halpin, and Chris Sprout, Grace Fine Chemical Manufacturing Services
|
Many tech transfer risks are avoidable with a single campus CDMO. With all manufacturing facilities on one site, drug sponsors can overcome obstacles and maintain speed en route to market.
|
|
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma
|
The FDA informed us again in April that the Bloomington, Indiana, facilities owned by Catalent until sold to Novo Nordisk in December 2024, have not solved quality issues. This adds to an FDA inspection/poor response and remediation history years long in the making. How is it we are witnessing this at a U.S. facility run by a name-brand CDMO and then Big Pharma? Catalent, for its part, wants to stop "inaccuracies in media coverage." Here's analysis from an experienced pharma professional and our own Chief Editor Louis Garguilo.
|
|
|
|
|
|
A Smarter Approach To Managing Safety Risks
|
|
By Mark F. Witcher, Ph.D.
|
Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
|
|
How To Capture Growth In The Expanding Metabolic Drug Market
|
|
Article | By Andrew Lewis, Andreas Reichl, and Matt Paterson, Quotient Sciences
|
Driven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges.
|
|
|
|
|
|
Accurate and Complete Characterization of Your API
|
|
E-Book | Altasciences
|
Assimilate how analytical testing can optimize API characterization, formulation, and bioavailability—and explore a case study showcasing Altasciences’ nanosuspension development expertise.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
